[218] Jang WI, Bae SH, Kim MS, et al. A phase 2
multicenter study of stereotactic body radiotherapy for hepatocellular
carcinoma: Safety and efficacy[J]. Cancer, 2020, 126(2): 363-72. [219] Kim N, Cheng J, Jung I, et al. Stereotactic body
radiation therapy vs. radiofrequency ablation in Asian patients with
hepatocellular carcinoma[J]. J Hepatol, 2020, 73(1): 121-9. [220] Su TS, Liang P, Liang J, et al. Long-Term
Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection
for Small Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017,
98(3): 639-46. [221] Wahl DR, Stenmark MH, Tao Y, et al. Outcomes
After Stereotactic Body Radiotherapy or Radiofrequency Ablation for
Hepatocellular Carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-9. [222] Meng MB, Cui YL, Lu Y, et al. Transcatheter
arterial chemoembolization in combination with radiotherapy for unresectable
hepatocellular carcinoma: a systematic review and meta-analysis[J]. Radiother
Oncol, 2009, 92(2): 184-94. [223] Ohri N, Dawson LA, Krishnan S, et al.
Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for
Future Study[J]. J Natl Cancer Inst, 2016, 108(9): djw133. [224] Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and
Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs
Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A
Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(5): 661-9. [225] Zeng ZC, Fan J, Tang ZY, et al. A comparison of
treatment combinations with and without radiotherapy for hepatocellular
carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]. Int J
Radiat Oncol Biol Phys, 2005, 61(2): 432-43. [226] Shen L, Xi M, Zhao L, et al. Combination Therapy
after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion:
Stereotactic Body Radiotherapy versus Sorafenib[J]. Cancers (Basel), 2018,
10(12). [227] Sun J, Yang L, Shi J, et al. Postoperative
adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An
open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140: 20-5. [228] Jihye C, Jinsil S. Application of
Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular
Carcinoma[J]. Liver Cancer, 2012, 1(3-4):216-25. [229] Soliman H, Ringash J, Jiang H, et al. Phase II
trial of palliative radiotherapy for hepatocellular carcinoma and liver
metastases[J]. J Clin Oncol, 2013, 31(31): 3980-6. [230] Sapisochin G, Barry A, Doherty M, et al.
Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in
patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J
Hepatol, 2017, 67(1): 92-9. [231] Wang WH, Wang Z, Wu JX, et al. Survival benefit
with IMRT following narrow-margin hepatectomy in patients with hepatocellular
carcinoma close to major vessels[J]. Liver Int, 2015, 35(12): 2603-10. [232] Wang L, Wang W, Rong W, et al. Postoperative
adjuvant treatment strategy for hepatocellular carcinoma with microvascular
invasion: a non-randomized interventional clinical study[J]. BMC Cancer, 2020,
20(1): 614. [233] Bujold A,
Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body
radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol,
2013, 31(13): 1631-9. [234] 曾昭冲. 肝细胞癌的立体定向放射治疗[J]. 中华肿瘤杂志, 2015, (9):650-2,3. [235] He J, Shi S, Ye L, et al. A randomized trial of
conventional fraction versus hypofraction radiotherapy for bone metastases from
hepatocellular carcinoma[J]. J Cancer, 2019, 10(17): 4031-7. [236] Hou JZ, Zeng ZC, Wang BL, et al. High dose
radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with
portal vein and/or inferior vena cava tumor thrombi is more feasible and
efficacious than conventional 3D-CRT[J]. Jpn J Clin Oncol, 2016, 46(4): 357-62.
[237] Zhang H, Chen Y, Hu Y, et al. Image-guided
intensity-modulated radiotherapy improves short-term survival for abdominal
lymph node metastases from hepatocellular carcinoma[J]. Ann Palliat Med, 2019,
8(5): 717-27. [238] Byun HK, Kim HJ, Im YR, et al. Dose escalation
in radiotherapy for incomplete transarterial chemoembolization of
hepatocellular carcinoma[J]. Strahlenther Onkol, 2020, 196(2): 132-41. [239] Hu Y, Zhou YK, Chen YX, et al. 4D-CT scans
reveal reduced magnitude of respiratory liver motion achieved by different
abdominal compression plate positions in patients with intrahepatic tumors
undergoing helical tomotherapy[J]. Med Phys, 2016, 43(7): 4335. [240] Kim TH, Koh YH, Kim BH, et al. Proton beam
radiotherapy vs. radiofrequency ablation for recurrent hepatocellular
carcinoma: A randomized phase III trial[J]. J Hepatol, 2021, 74(3): 603-12. [241] Bian H, Zheng JS, Nan G, et al. Randomized trial
of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous
radiofrequency ablation[J]. J Natl Cancer Inst, 2014, 106(9). [242] 中华医学会核医学分会转移性骨肿瘤治疗工作委员会. 氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017 年版)[J]. 中华核医学与分子影像杂志, 2018, 38(6):412-5. [243] Finn RS, Qin S, Ikeda M, et al. Atezolizumab
plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med,
2020, 382(20): 1894-905. [244] Finn RS, Qin S, Ikeda M, et al. IMbrave150:
Updated overall survival (OS) data from a global, randomized, open-label phase
III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in
patients (pts) with unresectable hepatocellular carcinoma (HCC)[J]. Journal of
Clinical Oncology, 2021, 39(3_suppl):abstr 267. [245] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a
bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet
Oncol, 2021, 22(7): 977-90. [246] Qin S, Bi F, Gu S, et al. Donafenib Versus
Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular
Carcinoma: A Randomized, Open-Label, arallel-Controlled Phase II-III Trial[J].
J Clin Oncol, 2021: Jco2100163. [247] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus
sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,
391(10126): 1163-73. [248] Llovet JM, Ricci S, Mazzaferro V, et al.
Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):
378-90. [249] Cheng AL, Kang YK, Chen Z, et al. Efficacy and
safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34. [250] Pressiani T, Boni C, Rimassa L, et al. Sorafenib
in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a
prospective feasibility analysis[J]. Ann Oncol, 2013, 24(2): 406-11. [251] Qin S, Bai Y, Lim HY, et al. Randomized,
multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin
versus doxorubicin as palliative chemotherapy in patients with advanced
hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-8. [252] Qin S, Cheng Y, Liang J, et al. Efficacy and
safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with
advanced hepatocellular carcinoma: a subgroup analysis of the EACH study[J].
Oncologist, 2014, 19(11): 1169-78.
|
